Defining post-acute COVID-19 syndrome (PACS) by an epigenetic biosignature in peripheral blood mononuclear cells

Clinical Epigenetics

Brief Report

Kristofer Hedman¹  Frida Nikesjö²  Eirini Apostolou³  Anders Rosén³  Maria Lerm⁴  Lovisa Karlsson⁴  Shumaila Sayyab⁴ 

[1] Department of Clinical Physiology, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden;Department of Respiratory Medicine in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden;Division of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden;Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Campus US, Medical Microbiology, Lab1, Floor 12, 581 85, Linköping, Sweden;

关键词: Post-acute COVID-19 syndrome;    PACS;    COVID-19;    SARS-CoV-2;    PBMC;    Epigenetics;    DNA methylation;    Biosignature;   

DOI  :  10.1186/s13148-022-01398-1

 received in 2022-07-01, accepted in 2022-12-05,  发布年份 2022

来源: Springer

【 摘 要 】

Post-acute COVID-19 syndrome (PACS) has been defined as symptoms persisting after clearance of a COVID-19 infection. We have previously demonstrated that alterations in DNA methylation (DNAm) status persist in individuals who recovered from a COVID-19 infection, but it is currently unknown if PACS is associated with epigenetic changes. We compared DNAm patterns in patients with PACS with those in controls and in healthy COVID-19 convalescents and found a unique DNAm signature in PACS patients. This signature unravelled modified pathways that regulate angiotensin II and muscarinic receptor signalling and protein–protein interaction networks that have bearings on vesicle formation and mitochondrial function.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 7

Fig. 4

Fig. 6